Literature DB >> 3474029

Purification, properties, and immunological characterization of folate-binding proteins from human leukemia cells.

E Sadasivan, M da Costa, S P Rothenberg, L Brink.   

Abstract

A new matrix for affinity chromatography using pteroylglutamic acid coupled to an epoxy-activated matrix via hexanediamine resulted in negligible ligand leakage and permitted the purification of soluble and membrane-associated folate-binding proteins from human leukemia cells contained in a human spleen. Two species of membrane-associated folate-binding proteins were purified from the solubilized membrane fraction of the tissue using 2 M guanidine-HCl to elute the proteins from the affinity matrix. The higher molecular weight binding protein had an Mr of approximately 310,000 and the smaller species had an Mr of approximately 28,000 by gel filtration. By SDS-polyacrylamide gel electrophoresis the smaller species of membrane-associated protein had a molecular weight of 35,500, but the molecular weight of the larger membrane-associated species could not be determined by this method because of the high concentration of residual Triton X-100 in the sample which interfered with the silver staining of the gel. Two folate-binding proteins, which by SDS-polyacrylamide gel electrophoresis had molecular weights of 34,500 and 32,000, were purified from the 44,000 X g supernatant fraction of the tissue homogenate by acid elution from the affinity matrix. Despite the different cell components from which the soluble and membrane-associated folate-binding proteins were purified, the amino acid compositions were similar, especially with respect to the apolar amino acids. All these forms of folate-binding proteins had higher affinity for oxidized than for reduced folates, and very low affinity for 5-formyltetrahydrofolate and methotrexate. Although these proteins cross-react with one antiserum raised previously to a folate-binding protein from other human leukemia cells, they do not cross-react with the folate-binding proteins purified from two other sources of human leukemia cells, from human placenta, or from the human KB cell line.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3474029     DOI: 10.1016/0304-4165(87)90145-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

Review 1.  Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.

Authors:  Tatiana A Slastnikova; Andrey A Rosenkranz; Michael R Zalutsky; Alexander S Sobolev
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Complementation of a methotrexate uptake defect in Chinese hamster ovary cells by DNA-mediated gene transfer.

Authors:  T M Underhill; W F Flintoff
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

3.  Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds.

Authors:  G Jansen; G R Westerhof; I Kathmann; G Rijksen; J H Schornagel
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Prevention of behavioral deficits in rats exposed to folate receptor antibodies: implication in autism.

Authors:  A Desai; J M Sequeira; E V Quadros
Journal:  Mol Psychiatry       Date:  2016-09-20       Impact factor: 15.992

5.  Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.

Authors:  Wolfgang Ebel; Eric L Routhier; Brian Foley; Sara Jacob; Jennifer M McDonough; Rina K Patel; Howard A Turchin; Qimin Chao; J Bradford Kline; Lloyd J Old; Martin D Phillips; Nicholas C Nicolaides; Philip M Sass; Luigi Grasso
Journal:  Cancer Immun       Date:  2007-03-09

6.  Exposure to Folate Receptor Alpha Antibodies during Gestation and Weaning Leads to Severe Behavioral Deficits in Rats: A Pilot Study.

Authors:  Jeffrey M Sequeira; Ankuri Desai; Maria I Berrocal-Zaragoza; Michelle M Murphy; Joan D Fernandez-Ballart; Edward V Quadros
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

Review 7.  Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review.

Authors:  Claudia Marchetti; Innocenza Palaia; Margherita Giorgini; Caterina De Medici; Roberta Iadarola; Laura Vertechy; Lavinia Domenici; Violante Di Donato; Federica Tomao; Ludovico Muzii; Pierluigi Benedetti Panici
Journal:  Onco Targets Ther       Date:  2014-07-10       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.